Combining the FtsZ-targeting prodrug TXA709 and the cephalosporin cefdinir confers synergy and reduces the frequency of resistance in methicillin-resistant Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 7, 2016, Pages 4290-4296

  Kaul, Malvika ^a   Mark, Lilly ^b,c   Parhi, Ajit K ^b,c   LaVoie, Edmond J ^c   Pilch, Daniel S ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b TAXIS Pharmaceuticals   (United States)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFDINIR; FTSZ PROTEIN; LINEZOLID; OXACILLIN; PRODRUG; PROTEIN INHIBITOR; TXA 709; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; CEPHALOSPORIN DERIVATIVE; CYTOSKELETON PROTEIN; FTSZ PROTEIN, BACTERIA; METICILLIN;

ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; IN VITRO STUDY; IN VIVO STUDY; LINEZOLID RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS INFECTION; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS; DRUG EFFECTS; GENETICS; METABOLISM; MICROBIAL SENSITIVITY TEST; PENICILLIN RESISTANCE; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CEPHALOSPORINS; CYTOSKELETAL PROTEINS; DRUG SYNERGISM; LINEZOLID; METHICILLIN; METHICILLIN RESISTANCE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; PRODRUGS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 84977083810     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00613-16     Document Type: Article

References (21)

1. Blair JM, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJ. 2015. Molecular mechanisms of antibiotic resistance. Nat Rev Microbiol 13:42-51. http://dx.doi.org/10.1038/nrmicro3380.
2. Davies J, Davies D. 2010. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev 74:417-433. http://dx.doi.org/10.1128/MMBR.00016-10.
3. Fischbach MA. 2011. Combination therapies for combating antimicrobial resistance. Curr Opin Microbiol 14:519-523. http://dx.doi.org/10.1016/j.mib.2011.08.003.
4. Tamma PD, Cosgrove SE, Maragakis LL. 2012. Combination therapy for treatment of infections with Gram-negative bacteria. Clin Microbiol Rev 25:450-470. http://dx.doi.org/10.1128/CMR.05041-11.
5. Anantharaman A, Rizvi MS, Sahal D. 2010. Synergy with rifampin and kanamycin enhances potency, kill kinetics, and selectivity of de novo-designed antimicrobial peptides. Antimicrob Agents Chemother 54:1693-1699. http://dx.doi.org/10.1128/AAC.01231-09.
6. Rahal JJ. 2006. Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 43(Suppl 2):S95-S99. http://dx.doi.org/10.1086/504486.
7. Kaul M, Mark L, Zhang Y, Parhi AK, Lyu YL, Pawlak J, Saravolatz S, Saravolatz LD, Weinstein MP, LaVoie EJ, Pilch DS. 2015. TXA709, an FtsZ-targeting benzamide prodrug with improved pharmacokinetics and enhanced in vivo efficacy against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 59:4845-4855. http://dx.doi.org/10.1128/AAC.00708-15.
8. Adams DW, Errington J. 2009. Bacterial cell division: assembly, maintenance and disassembly of the Z ring. Nat Rev Microbiol 7:642-653. http://dx.doi.org/10.1038/nrmicro2198.
9. Bi EF, Lutkenhaus J. 1991. FtsZ ring structure associated with division in Escherichia coli. Nature 354:161-164. http://dx.doi.org/10.1038/354161a0.
10. Erickson HP, Anderson DE, Osawa M. 2010. FtsZ in bacterial cytokinesis: cytoskeleton and force generator all in one. Microbiol Mol Biol Rev 74:504-528. http://dx.doi.org/10.1128/MMBR.00021-10.
11. Egan AJ, Vollmer W. 2013. The physiology of bacterial cell division. Ann N Y Acad Sci 1277:8-28. http://dx.doi.org/10.1111/j.1749-6632.2012.06818.x.
12. Kirkpatrick CL, Viollier PH. 2011. New(s) to the (Z-)ring. Curr Opin Microbiol 14:691-697. http://dx.doi.org/10.1016/j.mib.2011.09.011.
13. Lutkenhaus J, Pichoff S, Du S. 2012. Bacterial cytokinesis: from Z ring to divisome. Cytoskeleton 69:778-790. http://dx.doi.org/10.1002/cm.21054.
14. Pinho MG, Errington J. 2003. Dispersed mode of Staphylococcus aureus cell wall synthesis in the absence of the division machinery. Mol Microbiol 50:871-881. http://dx.doi.org/10.1046/j.1365-2958.2003.03719.x.
15. Tan CM, Therien AG, Lu J, Lee SH, Caron A, Gill CJ, Lebeau-Jacob C, Benton-Perdomo L, Monteiro JM, Pereira PM, Elsen NL, Wu J, Deschamps K, Petcu M, Wong S, Daigneault E, Kramer S, Liang L, Maxwell E, Claveau D, Vaillancourt J, Skorey K, Tam J, Wang H, Meredith TC, Sillaots S, Wang-Jarantow L, Ramtohul Y, Langlois E, Landry F, Reid JC, Parthasarathy G, Sharma S, Baryshnikova A, Lumb KJ, Pinho MG, Soisson SM, Roemer T. 2012. Restoring methicillin-resistant Staphylococcus aureus susceptibility to β-lactam antibiotics. Sci Transl Med 4:126ra135. http://dx.doi.org/10.1126/scitranslmed.3003592.
16. CLSI. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard - eighth edition, CLSI document M07-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
17. Kaul M, Mark L, Zhang Y, Parhi AK, LaVoie EJ, Pilch DS. 2013. Pharmacokinetics and in vivo antistaphylococcal efficacy of TXY541, a 1-methylpiperidine-4-carboxamide prodrug of PC190723. Biochem Pharmacol 86:1699-1707. http://dx.doi.org/10.1016/j.bcp.2013.10.010.
18. Kaul M, Parhi AK, Zhang Y, LaVoie EJ, Tuske S, Arnold E, Kerrigan JE, Pilch DS. 2012. A bactericidal guanidinomethyl biaryl that alters the dynamics of bacterial FtsZ polymerization. J Med Chem 55:10160-10176. http://dx.doi.org/10.1021/jm3012728.
19. Abbott Laboratories. 2007. Omnicef (Cefdinir) package insert. Abbott Laboratories, North Chicago, IL.
20. Sharma V, McNeill JH. 2009. To scale or not to scale: the principles of dose extrapolation. Br J Pharmacol 157:907-921. http://dx.doi.org/10.1111/j.1476-5381.2009.00267.x.
21. Sakamoto H, Hirose T, Nakamoto S, Hatano K, Shibayama F, Kikuchi H, Mine Y, Kuwahara S. 1988. Pharmacokinetics of FK482, a new orally active cephalosporin, in animals. J Antibiot (Tokyo) 41:1896-1905. http://dx.doi.org/10.7164/antibiotics.41.1896.